ACW FY2025 results - accelerating Alzheimers pivotal trial
Filed with ASX · · 4 pages · English
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- ACW Appendix 4E and 2025 annual report
- Actinogen June 2025 quarterly activity report & Appendix 4C
- A novel oral treatment for Alzheimer's: Actinogen's pivotal trial currently recruiting participants in the US
- Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline
- ACW accesses up to $13.8m in non-dilutive R&D tax funding
Later from Actinogen Medical
- ACW pharmacokinetics trial success
- Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states
- ACW successful FDA meeting on Alzheimers program
- Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease
- ACW receives initial $5.5m R&D tax incentive rebate
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical